Rate My Professor Alexander Menzies

Professor Alexander Menzies is a Medical Oncologist and Professor of Melanoma Medical Oncology at Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals. He received his PhD in 2015 for research exploring the biology of BRAF-mutant melanoma and biomarkers of response and resistance to targeted therapy. His main research interests are clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Since 2009 he has been an investigator on over 80 sponsored and investigator-led Phase I to III clinical trials of systemic therapies in melanoma. In the last five years he has authored over 85 publications with more than 2000 citations in journals such as Nature, Lancet Oncology, Nature Communications, Journal of Clinical Oncology, Annals of Oncology and Clinical Cancer Research. Professor Menzies conducts several investigator-led and sponsored clinical trials, manages the medical oncology clinical and biospecimen databases at MIA that underpin clinical and translational research, and serves as a faculty member and research committee member at MIA. He has co-established an international clinical research collaboration network between several major Australian, USA and European melanoma centres providing opportunities for junior research staff leading to high impact original research publications, and is a founding member of the international neoadjuvant melanoma consortium (INMC). In 2023 he received the NSW Premier's Award for Outstanding Mid-Career Researcher.

Professor Menzies holds appointments within the Faculty of Medicine and Health at the University of Sydney. His work focuses on advancing systemic therapies and understanding treatment responses in melanoma through clinical and translational research conducted at MIA and affiliated hospitals.